p21WAF1/CIP1 expression is a marker of poor prognosis in oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 34, Issue 5, 2005, Pages 274-279

  Nemes, Judit A ^a   Nemes, Zoltán ^b   Márton, Ildikó J ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Cyclin D1; Ki 67; Oral; p21; p53; Squamous cell carcinoma

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; CANCER INVASION; METABOLISM; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 17144378257     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2005.00310.x     Document Type: Article

References (55)

1. Matsuda H, Konishi N, Hiasa Y, et al. Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. J Oral Pathol Med 1996; 25: 232-8.
2. Kashiwazaki H, Tonoki H, Tada M, et al. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene 1997; 15: 2667-74.
3. Field JK, Spandidos DA. Expression of oncogenes in human tumors with special reference to the head and neck region. J Oral Pathol 1987; 16: 97-107.
4. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-7.
5. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-16.
6. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
7. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-4.
8. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994; 54: 3391-5.
9. Fan Z, Shang BY, Lu Y, Chou JL, Mendelsohn J. Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res 1997; 3: 1943-8.
10. Lukas J, Groshen S, Saffari B, et al. WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am J Pathol 1997; 150: 167-75.
11. Lu Y, Yamagishi N, Yagi T, Takebe H. Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells. Oncogene 1998; 16: 705-12.
12. Garcia del Muro X, Condom E, Vigues F, et al. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 2004; 100: 1859-67.
13. Rose SL, Goodheart MJ, DeYoung BR, Smith BJ, Buller RE. p21 expression predicts outcome in p53-null ovarian carcinoma. Clin Cancer Res 2003; 9: 1028-32.
14. Caffo O, Doglioni C, Veronese S, et al. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996; 2: 1591-9.
15. Lam KY, Law S, Tin L, Tung PH, Wong J. The clinicopathological significance of p21 and p53 expression in esophageal squamous cell carcinoma: an analysis of 153 patients. Am J Gastroenterol 1999; 94: 2060-8.
16. Sarbia M, Stahl M, zur Hausen A, et al. Expression of p21WAF1 predicts outcome of esophageal cancer patients treated by surgery alone or by combined therapy modalities. Clin Cancer Res 1998; 4: 2615-23.
17. Erber R, Klein W, Andl T, et al. Aberrant p21 (CIP1/WAF1) protein accumulation in head-and-neck cancer. Int J Cancer 1997; 74: 383-9.
18. Ibrahim SO, Lillehaug JR, Vasstrand EN. Mutations of the cell cycle regulatory genes p16INK4A and p21WAF1 and the metastasis-inducing gene S100A4 are infrequent and unrelated to p53 tumor suppressor gene status and data on survival in oropharyngeal squamous cell carcinomas. Anticancer Res 2003; 23: 4593-600.
19. Przybojewska B, Rydzynski K, Stepnik M, Jakubiak M, Kozak J, Szymczak W. Immunohistochemical evaluation of P21ras and P53 proteins expression in human non-small-cell lung cancers. Neoplasma 2003; 50: 198-203.
20. Liu CJ, Chang KW, Chao SY, et al. The molecular markers for prognostic evaluation of areca-associated buccal squamous cell carcinoma. J Oral Pathol Med 2004; 55: 327-34.
21. Kapranos N, Stathopoulos GP, Manolopoulos L, et al. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Res 2001; 21: 521-8.
22. Shoji T, Tanaka F, Takata T, et al. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 2002; 20: 3865-71.
23. Chien CY, Huang CC, Cheng JT, Chen CM, Hwang CF, Su CY. The clinicopathological significance of p53 and p21 expression in squamous cell carcinoma of hypopharyngeal cancer. Cancer Lett 2003; 201: 217-23.
24. Gomyo Y, Ikeda M, Osaki M, et al. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997; 79: 2067-72.
25. Jiang M, Shao ZM, Wu J, et al. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 1997; 74: 529-34.
26. Komiya T, Hosono Y, Hirashima T, et al. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 1997; 3: 1831-5.
27. Sobin LH, Wittekind C, eds. Head and Neck tumors. International Union Against Cancer (Union Internationale Contre le Cancer): TNM classification of malignant tumors. New York: Wiley-Liss, 1997; 20-4.
28. Pindborg JJ, Reichart PA, Smith CJ, van der Waal I. Histological typing of cancer and precancer of the oral mucosa. Berlin: Springer Verlag, 1997.
29. Sorrentino V, Nebreda AR, Alonso T, Santos E. Preparation, characterization and properties of monoclonal antibodies against intact H-ras p21 proteins. Oncogene 1989; 4: 215-22.
30. Vallance SJ, Lee HM, Roussel MF, et al. Monoclonal antibodies to mammalian D-type G1 cyclins. Hybridoma 1994; 13: 37-44.
31. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992; 151: 237-44.
32. Key G, Becker MH, Baron B, et al. Preparation and immunobiochemical characterization of new Ki-67 equivalent murine monoclonal antibodies (MIB 1-3) generated against recombinant parts of the Ki-67 antigen. Anal Cell Pathol 1992; 4: 181-9.
33. Xie X, Clausen OP, Boysen M. Prognostic significance of p21WAF1/CIP1 expression in tongue squamous cell carcinomas. Arch Otolaryngol Head Neck Surg 2002; 128: 897-902.
34. Kudo Y, Takata T, Ogawa I, Sato S, Nikai H. Expression of p53 and p21CIP1/WAF1 proteins in oral epithelial dysplasias and squamous cell carcinomas. Oncol Rep 1999; 6: 539-45.
35. Ng IO, Lam KY, Ng M, Regezi JA. Expression of p21/waf1 in oral squamous cell carcinomas-correlation with p53 and mdm2 and cellular proliferation index. Oral Oncol 1999; 35: 63-9.
36. van Oijen MGCT, Tilanus MGJ, Medema RH, Slootweg PJ. Expression of p21(Waf1/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression. J Oral Pathol Med 1998; 27: 367-75.
37. Shih HC, Shiozawa T, Kato K, et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol 2003; 34: 471-8.
38. Pasz-Walczak G, Kordek R, Faflik M. P21 (WAF1) expression in colorectal cancer: correlation with P53 and cyclin D1 expression, clinicopathological parameters and prognosis. Pathol Res Pract 2001; 197: 683-9.
39. Noda H, Maehara Y, Irie K, Kakeji Y, Yonemura T, Sugimachi K. Growth pattern and expressions of cell cycle regulator proteins p53 and p21WAF1/CIP1 in early gastric carcinoma. Cancer 2001; 92: 1828-35.
40. Lele SM, Pou AM, Ventura K, Gatalica Z, Payne D. Molecular events in the progression of recurrent respiratory papillomatosis to carcinoma. Arch Pathol Lab Med 2002; 126: 1184-8.
41. Giannoudis A, Herrington CS. Differential expression of p53 and p21 in low grade cervical squamous intraepithelial lesions infected with low, intermediate, and high risk human papillomaviruses. Cancer 2000; 89: 1300-7.
42. Xie HL, Su Q, He XS, et al. Expression of p21(WAF1) and p53 and polymorphism of p21(WAF1) gene in gastric carcinoma. World J Gastroenterol 2004; 10: 1125-31.
43. Warnakulasuriya KAAS, Tavassoli M, Johnson NW. Relationship of p53 overexpression to other cell cycle regulatory proteins in oral squamous cell carcinoma. J Oral Pathol Med 1998; 27: 376-81.
44. Sheikh MS, Garcia M, Zhan Q, Liu Y, Fornace AJ Jr. Cell cycle-independent regulation of p21Waf1/Cip1 and retinoblastoma protein during okadaic acid-induced apoptosis is coupled with induction of Bax protein in human breast carcinoma cells. Cell Growth Differ 1996; 7: 1599-607.
45. el-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-74.
46. Dulic V, Kaufmann WK, Wilson SJ, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76: 1013-23.
47. Cheng J, Huang H, Pak J, et al. Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. Cancer Res 2003; 63: 179-85.
48. Sanz-Ortega J, Valor C, Saez MC, et al. 3p21, 5q21, 9p21 and 17p13 allelic deletions accumulate in the dysplastic spectrum of laryngeal carcinogenesis and precede malignant transformation. Histol Histopathol 2003; 18: 1053-7.
49. Gonzalez-Moles MA, Galindo P, Gutierrez-Fernandez J, et al. P53 protein expression in oral squamous cell carcinoma. Survival analysis. Anticancer Res 2001; 21: 2889-94.
50. Kodani I, Osaki M, Shomori K, et al. Minichromosome maintenance 2 expression is correlated with mode of invasion and prognosis in oral squamous cell carcinomas. J Oral Pathol Med 2003; 32: 468-74.
51. Ostwald C, Gogacz P, Hillmann T, et al. p53 mutational spectra are different between squamous-cell carcinomas of the lip and the oral cavity. Int J Cancer 2000; 88: 82-6.
52. Omar EA, Behlouli H, Chevalier S, Aprikian AG. Relationship of p21(WAF-I) protein expression with prognosis in advanced prostate cancer treated by androgen ablation. Prostate 2001; 49: 191-9.
53. Zlotta AR, Noel JC, Fayt I, et al. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol 1999; 161: 792-8.
54. Jeannon JP, Soames J, Lunec J, Awwad S, Ashton V, Wilson JA. Expression of cyclin-dependent kinase inhibitor p21(WAF1) and p53 tumor suppressor gene in laryngeal cancer. Clin Otolaryngol 2000; 25: 23-7.
55. Yanamoto S, Kawasaki G, Yoshitomi I, Mizuno A. p53, mdm2, and p21 expression in oral squamous cell carcinomas: relationship with clinicopathologic factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94: 593-600.